Skip to main content
SpringerLink
Log in

Le terapie farmacologiche nelle fratture da fragilità

Drug therapy in osteoporotic fractures

  • Published:
Archivio di Ortopedia e Reumatologia

Abstract

Many therapeutic agents are currently available for osteoporotic fractures prevention, and their efficacy has been demonstrated in several clinical studies. Major evidences derive from randomized controlled trials or meta-analyses in which vertebral, non-vertebral and hip antifracture effect was tested. Here we summarize the principal data about drugs currently registered in Italy for the treatment of osteoporosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Bibliografia

  1. Rossini M, Piscitelli P, Fitto F et al (2005) Incidence and socioeconomic burden of hip fractures in Italy. Reumatismo 57:97–102

    PubMed  CAS  Google Scholar 

  2. Chapuy MC, Arlot ME, Duboeuf F et al (1992) Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 327:1637–1642

    Article  PubMed  CAS  Google Scholar 

  3. Chapuy MC, Arlot ME, Delmas PD, Meunier PJ (1994) Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 308:1081–1082

    Article  PubMed  CAS  Google Scholar 

  4. Chapuy MC, Pamphile R, Paris E et al (2002) Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int 13:257–264

    Article  PubMed  CAS  Google Scholar 

  5. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE (1997) Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337:670–676

    Article  PubMed  CAS  Google Scholar 

  6. Lips P, Graafmans WC, Ooms ME et al (1996) Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. Ann Intern Med 124:400–406

    PubMed  CAS  Google Scholar 

  7. Trivedi DP, Doll R, Khaw KT (2003) Effect of four monthly oral vitamin D3 (cholecalciferol) supplementations on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 326:469–474

    Article  PubMed  CAS  Google Scholar 

  8. Heikinheimo RJ, Inkovaara JA, Harju EJ et al (1992) Annual injection of vitamin D and fractures of aged bones. Calcif Tissue Int 51:105–110

    Article  PubMed  CAS  Google Scholar 

  9. Rossouw JE, Anderson GL, Prentice RL et al; Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333

    Article  PubMed  CAS  Google Scholar 

  10. Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637–645

    Article  PubMed  CAS  Google Scholar 

  11. Delmas PD, Genant HK, Crans GG et al (2003) Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 33:522–532

    Article  PubMed  CAS  Google Scholar 

  12. Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348: 1535–1541

    CAS  Google Scholar 

  13. Cummings SR, Black DM, Thompson DE et al, for the Fracture Intervention Trial Research Group (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077–2082

    Article  PubMed  CAS  Google Scholar 

  14. Karpf DB, Shapiro DR, Seeman E et al (1997) Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA 277:1159–1164

    Article  PubMed  CAS  Google Scholar 

  15. Reginster JY, Minne HW, Sorensen OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83–91

    Article  PubMed  CAS  Google Scholar 

  16. Watts NB, Josse RG, Hamdy RC et al (2003) Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 88:542–549

    Article  PubMed  CAS  Google Scholar 

  17. McClung MR, Geusens P, Miller PD et al; Hip Intervention Program Study Group (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333–340

    Article  PubMed  CAS  Google Scholar 

  18. Cranney A, Tugwell P, Adachi J et al (2002) Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 23:517–523

    Article  PubMed  CAS  Google Scholar 

  19. Chesnut CH 3rd, Skag A, Christiansen C et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241–1249

    Article  CAS  Google Scholar 

  20. Black DM, Delmas PD, Eastell R et al; HORIZON Pivotal Fracture Trial (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822

    Article  PubMed  CAS  Google Scholar 

  21. Meunier PJ, Slosman DO, Delmas PD et al (2002) Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis: a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 87:2060–2066

    Article  PubMed  CAS  Google Scholar 

  22. Meunier PJ, Roux C, Seeman E et al (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459–468

    Article  PubMed  CAS  Google Scholar 

  23. Reginster JY, Felsenberg D, Boonen S et al (2008) Effects of longterm strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum 58:1687–1695

    Article  PubMed  CAS  Google Scholar 

  24. Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441

    Article  PubMed  CAS  Google Scholar 

  25. Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Day Hospital di Reumatologia, Istituto Ortopedico G. Pini, Milano, Italy

    M. Manara

Authors
  1. M. Manara
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Manara, M. Le terapie farmacologiche nelle fratture da fragilità. Arch Ortop Reumatol 122, 20–21 (2011). https://doi.org/10.1007/s10261-011-0040-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10261-011-0040-4

Search

Navigation